We aimed to investigate , in patients with ST-segment elevation myocardial infarction ( STEMI ) , whether the previously reported clinical benefits of sirolimus-eluting stent ( s ) ( SES ) in terms of reducing a major adverse cardiac and cerebrovascular event ( MACCE ) compared with bare-metal stent ( s ) ( BMS ) were maintained over a 5-year time period .